Related Experiment Videos
Morphological differentiation of human neuroblastoma cell lines by a new synthetic polyprenoic acid (E5166)
T Sugimoto1, T Sawada, T Matsumura
1Children's Research Hospital, Kyoto Prefectural University of Medicine, Japan.
Abstract:
The prognosis of patients with advanced neuroblastoma remains poor despite recent progress in chemo/radiotherapy. Therapeutic trials on the induction of differentiation of neuroblastoma by chemical and biological agents have been attempted to improve patients' prognosis. Recently a new synthetic polyprenoic acid, E5166, having retinoic acid properties, has been described. In this study two human neuroblastoma cell lines, KP-N-RT(LN) and SK-N-DZ, were treated in vitro by E5166. Morphological differentiation of KP-N-RT(LN) and SK-N-DZ cells could be induced by E5166 in the presence of 1.7 X 10(-5) M E5166 for 10 days in culture. Levels of catecholamines (dopamine, adrenaline, and noradrenaline) were not elevated in the E5166-differentiated cells. E5166-induced differentiation may not be cyclic AMP dependent, since levels of cyclic AMP did not increase after exposure of cells to this agent. No significant increase in neuron-specific enolase levels could be demonstrated in E5166-treated neuroblastoma as compared to control untreated cells. E5166 treatment of KP-N-RT(LN) and SK-N-DZ cells was found to inhibit colony formation in soft agar in a dose-dependent manner. Colonies of KP-N-RT(LN) cells in the presence of E5166 showed morphological differentiation as defined by the expression of long neurite processes. E5166 is a less toxic reagent than the retinoic acids used for the induction of differentiation, it can be administered to patients p.o., and the concentration of E5166 which induces the morphological differentiation in vitro can be achievable in vivo. Therefore our study suggests that E5166 could be a useful therapeutic agent in advanced neuroblastoma to differentiate residual anaplastic tumor cells to a benign form (ganglioneuroma) after surgery and chemotherapy.
Insights
A new synthetic compound, E5166, effectively induces morphological differentiation in neuroblastoma cells in vitro. This agent shows potential as a less toxic therapeutic for advanced neuroblastoma, aiming to convert tumor cells into a benign form.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Advanced neuroblastoma has a poor prognosis despite current chemo/radiotherapy.
- Therapeutic strategies to induce neuroblastoma cell differentiation are being explored.
- A novel synthetic polyprenoic acid, E5166, with retinoic acid-like properties has emerged.
Purpose of the Study:
- To investigate the in vitro effects of E5166 on human neuroblastoma cell lines.
- To assess E5166's potential to induce morphological differentiation and inhibit tumor growth.
- To evaluate E5166 as a potential therapeutic agent for advanced neuroblastoma.
Main Methods:
- Two human neuroblastoma cell lines (KP-N-RT(LN) and SK-N-DZ) were treated with E5166 in vitro.
- Morphological differentiation was assessed, along with levels of catecholamines and cyclic AMP.
- Neuron-specific enolase levels and colony formation in soft agar were analyzed.
Main Results:
- E5166 induced significant morphological differentiation in both cell lines after 10 days.
- E5166 inhibited colony formation in soft agar in a dose-dependent manner.
- E5166 treatment did not elevate catecholamine or cyclic AMP levels, nor neuron-specific enolase.
Conclusions:
- E5166 effectively induces differentiation and inhibits proliferation of neuroblastoma cells in vitro.
- E5166 demonstrates lower toxicity and better oral bioavailability compared to retinoic acids.
- E5166 shows promise as a therapeutic agent to differentiate residual neuroblastoma cells into a benign form.